

# **Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses**

Dec 06, 2018

---

**Source URL:** <https://qa1.novartis.us/news/media-releases/novartis-investigational-by1719-alpelisib-plus-fulvestrant-consistently-improved-pfs-patients-pik3ca-mutated-hrher2-advanced-breast-cancer-new-solar-1-analyses-0>

## **List of links present in page**

1. <https://qa1.novartis.us/news/media-releases/novartis-investigational-by1719-alpelisib-plus-fulvestrant-consistently-improved-pfs-patients-pik3ca-mutated-hrher2-advanced-breast-cancer-new-solar-1-analyses-0>